Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 574 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Locations: - AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Kaiser Permanente Dublin — Dublin, California
+ 149 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Phoenix Childrens Hospital — Phoenix, Arizona
+ 103 more sites in the U.S.
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Locations: - University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- City of Hope Corona — Corona, California
+ 70 more sites in the U.S.
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Locations: - Banner MD Anderson Cancer Center — Phoenix, Arizona
- Barrow Neurological Institute — Phoenix, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
+ 64 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma. After completion of surgery, the standar…
Sponsor: NRG Oncology
NCT ID: NCT07452458
Locations: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
+ 51 more sites in the U.S.
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Locations: - University of Alabama — Birmingham, Alabama
- Mayo Clinic - Arizona — Phoenix, Arizona
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
+ 43 more sites in the U.S.
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- University of California, San Diego — La Jolla, California
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
+ 39 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Locations: - Mayo Clinic Hospital — Phoenix, Arizona
- University of Southern California — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
+ 33 more sites in the U.S.
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Locations: - Mayo Clinic Arizona — Phoenix, Arizona
- Kaiser Permanente — Los Angeles, California
- UCLA — Los Angeles, California
+ 20 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Locations: - HonorHealth Scottsdale Osborn Medical Center — Scottsdale, Arizona
- Keck Medicine of USC — Los Angeles, California
- Advent Health — Orlando, Florida
+ 10 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Locations: - St. Joseph's Hospital and Medical Center — Phoenix, Arizona
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Broward Health — Fort Lauderdale, Florida
+ 9 more sites in the U.S.